Table 1.
Characteristics of rheumatoid arthritis–fibroblast-like synoviocytes (RA-FLS) and osteoarthritis–FLS (OA-FLS) donors.
| Donor | Diagnosis | Sex | Ethnicity | Age | Disease Duration (Years) | RF | Medication(s) | Origin |
|---|---|---|---|---|---|---|---|---|
| OA-1 | OA | Female | Caucasian | UN | UN | N/A | None | PSG |
| OA-2 | OA | Female | African American | 56 | 2 | N/A | None | PSG |
| OA-3 | OA | Female | Caucasian | 56 | 5 | N/A | None | PSG |
| OA-4 | OA | Male | Caucasian | 56 | 25 | N/A | None | PSG |
| RA-1 | RA | Female | Hispanic | 64 | >10 | + | Prednisone, Methotrexate | PSG |
| RA-2 | RA | Female | Caucasian | 66 | 20 | + | Prednisone, Etanercept | PSG |
| RA-3 | RA | Male | Hispanic | 48 | <1 | + | DMARD, Prednisone | Asterand |
| RA-4 | RA | Female | African American | 49 | 11 | + | Prednisone, Plaquenil | PSG |
| RA-5 | RA | Female | Caucasian | 71 | 3 | + | Methotrexate, Prednisone | PSG |
| RA-6 | RA | Male | Caucasian | 54 | >10 | + | Etanercept | PSG |
| RA-7 | RA | Female | Caucasian | 39 | 3 | + | NSAID | Asterand |
N/A: not applicable; UN: unknown; RF: rheumatoid factor; PSG: Dr. P.S. Gulko; DMARD: disease-modifying anti-rheumatic drug; NSAID: non-steroid anti-inflammatory drug.